GYRE
NASDAQ · Biotechnology
Gyre Therapeutics Inc
$6.30
+0.17 (+2.77%)
Open$6.14
Previous Close$6.13
Day High$6.30
Day Low$6.14
52W High$9.42
52W Low$5.44
Volume—
Avg Volume82.0K
Market Cap606.21M
P/E Ratio—
EPS$-0.08
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+374.9% upside
Current
$6.30
$6.30
Target
$29.92
$29.92
$20.05
$29.92 avg
$33.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 109.59M | 231.94M | 230.03M |
| Net Income | 4.72M | -34,891,358 | -29,454,556 |
| Profit Margin | 4.3% | -15.0% | -12.8% |
| EBITDA | 13.13M | -32,635,653 | -32,852,234 |
| Free Cash Flow | — | -26,269,864 | -27,800,469 |
| Rev Growth | +428.5% | -3.5% | +14.1% |
| Debt/Equity | — | 0.25 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |